As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma

Ryosuke Desaki, Genta Sawada, Hiroshi Okumura, Ryuji Ikeda, Kan Tanabe, Hisateru Komatsu, Koshi Mimori, Masaki Mori, Yoshiaki Kita, Yasuto Uchikado, Takaaki Arigami, Yoshikazu Uenosono, Tetsuhiro Owaki, Sumiya Ishigami, Shoji Natsugoe

Research output: Contribution to journalArticle

Abstract

Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.

Original languageEnglish
Pages (from-to)586-593
Number of pages8
JournalAnnals of Surgical Oncology
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Histidine
Cysteine
Therapeutics
Galectin 3
Esophageal Squamous Cell Carcinoma
Cell Line
Neoplasm Genes
Esophageal Neoplasms
Yeasts
Lymph Nodes
Neoplasm Metastasis
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma. / Desaki, Ryosuke; Sawada, Genta; Okumura, Hiroshi; Ikeda, Ryuji; Tanabe, Kan; Komatsu, Hisateru; Mimori, Koshi; Mori, Masaki; Kita, Yoshiaki; Uchikado, Yasuto; Arigami, Takaaki; Uenosono, Yoshikazu; Owaki, Tetsuhiro; Ishigami, Sumiya; Natsugoe, Shoji.

In: Annals of Surgical Oncology, Vol. 24, No. 2, 01.02.2017, p. 586-593.

Research output: Contribution to journalArticle

Desaki, R, Sawada, G, Okumura, H, Ikeda, R, Tanabe, K, Komatsu, H, Mimori, K, Mori, M, Kita, Y, Uchikado, Y, Arigami, T, Uenosono, Y, Owaki, T, Ishigami, S & Natsugoe, S 2017, 'As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma', Annals of Surgical Oncology, vol. 24, no. 2, pp. 586-593. https://doi.org/10.1245/s10434-015-5031-0
Desaki, Ryosuke ; Sawada, Genta ; Okumura, Hiroshi ; Ikeda, Ryuji ; Tanabe, Kan ; Komatsu, Hisateru ; Mimori, Koshi ; Mori, Masaki ; Kita, Yoshiaki ; Uchikado, Yasuto ; Arigami, Takaaki ; Uenosono, Yoshikazu ; Owaki, Tetsuhiro ; Ishigami, Sumiya ; Natsugoe, Shoji. / As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma. In: Annals of Surgical Oncology. 2017 ; Vol. 24, No. 2. pp. 586-593.
@article{20cb02dac5234aff9e0659700552f7e3,
title = "As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma",
abstract = "Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.",
author = "Ryosuke Desaki and Genta Sawada and Hiroshi Okumura and Ryuji Ikeda and Kan Tanabe and Hisateru Komatsu and Koshi Mimori and Masaki Mori and Yoshiaki Kita and Yasuto Uchikado and Takaaki Arigami and Yoshikazu Uenosono and Tetsuhiro Owaki and Sumiya Ishigami and Shoji Natsugoe",
year = "2017",
month = "2",
day = "1",
doi = "10.1245/s10434-015-5031-0",
language = "English",
volume = "24",
pages = "586--593",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma

AU - Desaki, Ryosuke

AU - Sawada, Genta

AU - Okumura, Hiroshi

AU - Ikeda, Ryuji

AU - Tanabe, Kan

AU - Komatsu, Hisateru

AU - Mimori, Koshi

AU - Mori, Masaki

AU - Kita, Yoshiaki

AU - Uchikado, Yasuto

AU - Arigami, Takaaki

AU - Uenosono, Yoshikazu

AU - Owaki, Tetsuhiro

AU - Ishigami, Sumiya

AU - Natsugoe, Shoji

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.

AB - Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84949949110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949949110&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-5031-0

DO - 10.1245/s10434-015-5031-0

M3 - Article

C2 - 26676980

AN - SCOPUS:84949949110

VL - 24

SP - 586

EP - 593

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -